Doximity’s first quarter results were met with a sharply negative market reaction, as management pointed to a combination of elevated AI-related expenses and persistent caution among pharmaceutical customers. CEO Jeffrey Tangney cited rapid uptake of Doximity’s AI workflow tools by physicians and highlighted a notable increase in engagement, but acknowledged that macro uncertainty and shorter-term spending commitments from clients weighed on the business. Management also addressed the drag on profitability from higher AI compute costs, noting that investments in platform capabilities and brand marketing led to a significant margin contraction.
Is now the time to buy DOCS? Find out in our full research report (it’s free for active Edge members).
Doximity (DOCS) Q1 CY2026 Highlights:
- Revenue: $145.4 million vs analyst estimates of $145 million (5.1% year-on-year growth, in line)
- Adjusted EPS: $0.26 vs analyst expectations of $0.28 (7.9% miss)
- Adjusted Operating Income: $63.63 million vs analyst estimates of $62.02 million (43.8% margin, 2.6% beat)
- Revenue Guidance for Q2 CY2026 is $151.5 million at the midpoint, below analyst estimates of $153.1 million
- EBITDA guidance for the upcoming financial year 2027 is $329 million at the midpoint, below analyst estimates of $373.3 million
- Operating Margin: 17.1%, down from 35.2% in the same quarter last year
- Billings: $185.3 million at quarter end, in line with the same quarter last year
- Market Capitalization: $3.56 billion
While we enjoy listening to the management's commentary, our favorite part of earnings calls are the analyst questions. Those are unscripted and can often highlight topics that management teams would rather avoid or topics where the answer is complicated. Here is what has caught our attention.
Our Top 5 Analyst Questions From Doximity’s Q1 Earnings Call
- Brian Peterson (Raymond James) asked about the size and timing of the AI opportunity. CEO Jeffrey Tangney cited strong pharma interest and described the market as "multi-billion dollar," but emphasized that regulatory review will delay revenue.
- Michael Cherny (Leerink Partners) pressed on AI investment discipline. Tangney said compute spending would rise with engagement, prioritizing accuracy and peer review, while Perry Gold noted the need to balance R&D with ROI for physicians.
- Glen Santangelo (Barclays) questioned regulatory and competitive risks in the new AI ad offering. Tangney explained the complexity of keyword targeting and compliance, while Gold described the product as "additive" but requiring a different sales and approval process.
- Elizabeth Anderson (Evercore ISI) asked about margin implications from AI investments and new leadership. Gold detailed higher compute and marketing spend, while Tangney highlighted Sonefeldt's strategic fit given his experience at LinkedIn.
- Ryan MacDonald (Needham & Company) inquired about unlocking incremental budget and pricing strategy. Tangney pointed to AI Search as a new avenue for client spend, while Gold stressed no plans to compete in low-cost ad segments.
Catalysts in Upcoming Quarters
Looking ahead, our analysts will watch (1) the rate of adoption and monetization for Doximity’s commercial AI Search suite among pharma clients, (2) the pace of margin recovery as AI-related costs normalize and free cash flow trends stabilize, and (3) signs of renewed budget commitment from pharmaceutical clients as macro and policy visibility improve. Execution on these fronts will determine whether Doximity’s AI investments can translate into sustainable growth.
Doximity currently trades at $19.15, down from $23.39 just before the earnings. Is there an opportunity in the stock?The answer lies in our full research report (it’s free).
The Best Stocks for High-Quality Investors
ALSO WORTH WATCHING: Top 5 Momentum Stocks. The best time to own a great stock is when the market is finally noticing it. These aren't just high-quality businesses. Something is happening with them right now. Elite fundamentals meeting near-term momentum - both boxes checked at the same time.
Find out which stocks our AI platform is flagging this week. See this week's Strong Momentum stocks - FREE. Get Our Strong Momentum Stocks for Free HERE.
Stocks that have made our list include now familiar names such as Nvidia (+1,326% between June 2020 and June 2025) as well as under-the-radar businesses like the once-small-cap company Comfort Systems (+782% five-year return). Find your next big winner with StockStory today.
